Clinical Research Directory

Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer

Sponsor: The Netherlands Cancer Institute

Summary

Investigator-initiated, international, multicentre, randomized, open-label, (neo)adjuvant phase III study in target population (stage III, HER2-negative, BRCA1-like breast cancer patients) comparing optimized standard-dose chemotherapy with intensified, alkylating chemotherapy with stem cell rescue.

Official title: Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients With Personalized Therapy (SUBITO) - an International Randomized Phase III Trial

Key Details

Conditions

Interventions

Locations (11)